Compare Nutanix Inc (NTNX) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs Tenet Healthcare Corporation — how do they compare? Nutanix Inc trades at $73.95 (market cap $19.78B), while Tenet Healthcare Corporation trades at $262.7 (market cap $20.98B). The key difference: Nutanix Inc and Tenet Healthcare Corporation are close in size by market cap, and Nutanix Inc is trading nearer its 52-week high, Tenet Healthcare Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nutanix Inc for 17 Days and Tenet Healthcare Corporation for 15 Days on average.
| NTNX | THC | |
|---|---|---|
Market Cap | $19.78B | $20.98B |
Volume | 1,717,619 | 428,008 |
Sector | Technology | Health |
52-Week High | $73.42 | $280.77 |
52-Week Low | $34.41 | $161.37 |
Typical Hold Time | 17 Days | 15 Days |
Enterprise Value | $18.94B | $32.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $73.24, down slightly by 0.25% today, but maintains a bullish technical outlook with strong analyst support. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.60 beating expectations of $0.49, and impressive profitability with an 86.8% gross margin. Recent Gartner Magic Quadrant recognitions highlight competitive strength in virtualization and container management platforms, supporting positive market sentiment.
The investment outlook remains positive with a consensus price target of $76.11 representing 4% upside potential. Key opportunities include external storage partnerships and AI growth initiatives, while risks involve high valuation multiples (EV/EBITDA of 46.22) and negative ROE of -395.76%. Institutional ownership trends and 62.5% analyst buy ratings suggest continued Wall Street confidence in the company's execution.
Tenet Healthcare (THC) trades at $261.07, up 0.48% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 82.83% gross margins and consistent earnings beats, while trading at attractive valuations including a 10.07 P/E ratio. Recent news highlights upcoming Q3 2026 earnings on October 29th and positive coverage of the company's growth prospects despite surgical volume challenges.
THC presents a compelling investment case with strong analyst support (81% buy ratings) and a $283.36 consensus target offering 8.5% upside. The healthcare provider shows improving profitability with net margins expected to reach 9.89% in 2026. Key risks include capital allocation sustainability and potential volatility around upcoming earnings, but the combination of value pricing and growth momentum supports a positive outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
